SCHEMBL7076972

SCHEMBL7076972

CN(C)c1ccc2oc(-c3ccccc3)c(O)c(=O)c2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.69
MAPT P10636 8/20 0.69
CYP3A4 P08684 8/20 0.62
MEN1 O00255 8/20 0.62
KMT2A Q03164 8/20 0.62
TP53 P04637 5/20 0.62
ALOX15 P16050 3/20 0.62
MAPK1 P28482 3/20 0.62
LMNA P02545 2/20 0.62
CA12 O43570 1/20 0.62
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
ABCB1 P08183 1/20 0.62
CALM1 P0DP23 1/20 0.62
AR P10275 1/20 0.62
PKM P14618 1/20 0.62
CYP1B1 Q16678 1/20 0.62
CA9 Q16790 1/20 0.62
HSD17B10 Q99714 6/20 0.57
CASP1 P29466 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30566291 0.83 TP53 (0.72) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL1106639 0.83 TP53 (0.72) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL17353581 0.83 MAPT (0.72) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL4650064 0.82 MAPT (1.00) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL7691881 0.82 KDM4E (0.70) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL1627936 0.81 CYP3A4 (0.82) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL15456750 0.81 CYP3A4 (0.82) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL74701 0.79 CYP3A4 (0.74) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL6700894 0.79 KDM4E (0.70) KDM4EMAPTCYP3A4MEN1KMT2A
SCHEMBL5130608 0.79 MAPT (0.70) KDM4EMAPTCYP3A4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610738-B2 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2003-08-26 US disclosed
EP-1322632-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES Biogal Pharmaceutical Co., Ltd (HU) 2003-07-02 EP disclosed
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-09-12 US disclosed
WO-2002024677-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-03-28 WO disclosed
WO-2002024676-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones CBR3, FOS, CBR1 KDM4E 366/4885MAPT 3319/4885CYP3A4 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.